Xintela AB Asset Resilience Ratio

Latest as of September 2025: 37.25%

Xintela AB asset resilience ratio. Xintela AB (XINT) has an Asset Resilience Ratio of 37.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Xintela AB defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr3.38 Million
≈ $363.85K USD Cash + Short-term Investments

Total Assets

Skr9.08 Million
≈ $976.72K USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Xintela AB (2016–2024)

Asset resilience ratio of Xintela AB from 2016 to 2024. This chart shows how Xintela AB's Asset Resilience Ratio has changed over time. Read Xintela AB (XINT) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Xintela AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Xintela AB asset portfolio.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr3.38 Million 37.25%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr3.38 Million 37.25%

Asset Resilience Insights

  • Very High Liquidity: Xintela AB maintains exceptional liquid asset reserves at 37.25% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Xintela AB Industry Peers by Asset Resilience Ratio

Compare Xintela AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hyloris Developmentsen Sa
BR:HYL
Biotechnology 1.36%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Biotechnology 53.11%
Gempharmatech Co. Ltd. A
SHG:688046
Biotechnology 23.95%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 74.48%
Inventiva S.A
PA:IVA
Biotechnology 52.73%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
Biotechnology 4.98%

Xintela AB Asset Resilience Ratio by Year (2016–2024)

Xintela AB asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Xintela AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 67.26% Skr16.68 Million
≈ $1.80 Million
Skr24.80 Million
≈ $2.67 Million
+24.81pp
2023-12-31 42.45% Skr7.81 Million
≈ $840.37K
Skr18.39 Million
≈ $1.98 Million
+8.42pp
2022-12-31 34.03% Skr8.34 Million
≈ $897.84K
Skr24.52 Million
≈ $2.64 Million
-14.38pp
2021-12-31 48.41% Skr11.98 Million
≈ $1.29 Million
Skr24.74 Million
≈ $2.66 Million
-20.85pp
2020-12-31 69.26% Skr33.60 Million
≈ $3.62 Million
Skr48.51 Million
≈ $5.22 Million
+66.85pp
2019-12-31 2.41% Skr412.00K
≈ $44.34K
Skr17.09 Million
≈ $1.84 Million
-60.74pp
2018-12-31 63.16% Skr31.40 Million
≈ $3.38 Million
Skr49.71 Million
≈ $5.35 Million
-13.49pp
2017-12-31 76.65% Skr21.91 Million
≈ $2.36 Million
Skr28.59 Million
≈ $3.08 Million
-2.93pp
2016-12-31 79.58% Skr18.98 Million
≈ $2.04 Million
Skr23.85 Million
≈ $2.57 Million
--
pp = percentage points

About Xintela AB

ST:XINT Sweden Biotechnology
Market Cap
$11.13 Million
Skr103.39 Million SEK
Market Cap Rank
#26642 Global
#561 in Sweden
Share Price
Skr0.15
Change (1 day)
-5.16%
52-Week Range
Skr0.15 - Skr0.39
All Time High
Skr8.60
About

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indicati… Read more